Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Catalyst Pharm Inc (NQ: CPRX ) 19.56 -0.39 (-1.95%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 799,328 Open 20.00 Bid (Size) 19.50 (4) Ask (Size) 19.94 (1) Prev. Close 19.95 Today's Range 19.53 - 20.02 52wk Range 11.55 - 21.66 Shares Outstanding 102,780,151 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan September 24, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire A Biotech Breakout Will Be Led By Small Caps September 23, 2024 It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. Via Talk Markets Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Performance YTD +14.32% +14.32% 1 Month -4.45% -4.45% 3 Month +30.05% +30.05% 6 Month +22.71% +22.71% 1 Year +60.72% +60.72% More News Read More Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase. September 19, 2024 Via Chartmill NASDAQ:CPRX is showing good growth, while it is not too expensive. September 13, 2024 Via Chartmill Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout. August 29, 2024 Via Chartmill The Latest Analyst Ratings For Catalyst Pharmaceuticals August 12, 2024 Via Benzinga A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals June 03, 2024 Via Benzinga Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark September 05, 2024 Via Investor's Business Daily Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers August 29, 2024 Via Investor's Business Daily Biohaven Stock Earns Relative Strength Rating Upgrade August 21, 2024 Via Investor's Business Daily SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating August 21, 2024 Via Investor's Business Daily Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents. August 21, 2024 Via Chartmill NASDAQ:CPRX stands out as a growth opportunity that won't break the bank. August 21, 2024 Via Chartmill Immunome Stock Sees RS Rating Jump To 91 August 20, 2024 Via Investor's Business Daily Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences August 20, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire PTC Therapeutics Stock Earns RS Rating Upgrade To 83 August 19, 2024 Via Investor's Business Daily Top 3 Health Care Stocks That May Crash In August August 14, 2024 Via Benzinga CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 August 07, 2024 Via InvestorPlace Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update August 07, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Top 3 Health Care Stocks You May Want To Dump This Quarter July 30, 2024 Via Benzinga Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 Via Investor's Business Daily Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada July 24, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024 July 22, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Via Talk Markets Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® May 30, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.